HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Puma Biotechnology (NASDAQ:PBYI) and maintained an $8 price target.
September 20, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Puma Biotechnology's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and an $8 price target.
Analyst ratings and price targets can significantly influence a company's stock price. In this case, HC Wainwright & Co. has reiterated a 'Buy' rating on Puma Biotechnology, indicating a positive outlook for the company. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100